Stocks · Healthcare · Biotechnology
Fortress Biotech, Inc. FBIO
$2.03 -1.93% Close, Oct 2, 2026 · NASDAQ · Market cap $67.4M
Weak trendInexpensive vs sector
Next earnings report: Nov 16, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -42.9% from -182.5% a year earlier.
- The diluted share count rose 24.1% in a year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth42Weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 39%
- Revenue growth, 3-year CAGRBottom 14%
- Revenue growth accelerationTop 36%
Quality48Neutral
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 43%
- Gross marginBottom 48%
- Operating marginBottom 36%
- Cash conversion (OCF / net income)Bottom 26%
- Accruals (lower is better)Bottom 39%
- Net debt / EBITDA (lower is better)Top 22%
- Interest coverBottom 45%
Value100Exceptional
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 1%
- Free-cash-flow yieldTop 1%
Momentum18Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 39%
- 6-month returnBottom 23%
- 1-year return vs S&P 500Bottom 28%
- Distance from 52-week highBottom 22%
- Trend checklist (0–4)Bottom 14%
Revisions98Exceptional
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 27%
Stability69Positive
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 46%
- Maximum drawdown, 3 yearsBottom 45%
- Beta vs S&P 500 (lower is better)Top 25%
- Net debt / EBITDA (lower is better)Top 22%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 14.5% | 15.5% | ↑ |
| Gross margin | 64.9% | 62.5% | ↓ |
| Operating margin | -182.5% | -42.9% | ↑ |
| FCF margin | -135.1% | 183.8% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 15.5% | 14.5% | ↑ | Top 39% |
| Gross margin | 62.5% | 64.9% | ↓ | Bottom 48% |
| Operating margin | -42.9% | -182.5% | ↑ | Bottom 36% |
| Net margin | 163.3% | -24.8% | ↑ | — |
| Free-cash-flow margin | 183.8% | -135.1% | ↑ | — |
| Return on invested capital | -10.8% | — | Top 43% | |
| Revenue growth, 3-year CAGR | -5.8% | — | Bottom 14% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.13×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.3%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +111.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.82×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -3.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.70%
- Net buyback yield (TTM)
- -10.68%
- Shareholder yield
- -9.98%
- Share count change, 1 year
- +24.1%
- Share count change, 3-year CAGR
- +71.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- +2.6%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $5.00
- Target vs current price
- +146.3%
- Analysts with a rating
- 6
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +60.0% | +8.4% | +3.6% | -6.5% | — |
| May 14, 2026 | +1381.8% | +3.1% | +18.8% | +23.8% | +23.3% |
| Mar 31, 2026 | -150.0% | +3.3% | -13.0% | -17.0% | +11.9% |
| Nov 14, 2025 | +125.6% | +5.2% | +1.6% | +17.7% | +47.4% |
| Aug 14, 2025 | -48.4% | +1.6% | +6.2% | +98.4% | +30.6% |
| May 15, 2025 | -9.1% | +7.2% | +2.4% | +18.1% | +15.7% |
| Mar 31, 2025 | +67.1% | -3.1% | -5.6% | +4.3% | +11.8% |
| Nov 14, 2024 | -181.5% | -4.8% | -4.8% | +20.6% | +4.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.08 | -$0.20 | +60.0% | $18.7M |
| May 14, 2026 | $2.82 | -$0.22 | +1381.8% | $16.0M |
| Mar 31, 2026 | -$0.21 | $0.42 | -150.0% | $16.1M |
| Nov 14, 2025 | $0.11 | -$0.43 | +125.6% | $17.6M |
| Aug 14, 2025 | -$0.46 | -$0.31 | -48.4% | $16.4M |
| May 15, 2025 | -$0.48 | -$0.44 | -9.1% | $13.1M |
| Mar 31, 2025 | -$0.26 | -$0.79 | +67.1% | $15.1M |
| Nov 14, 2024 | -$0.76 | -$0.27 | -181.5% | $14.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 0.8× | — | — | Top 1% |
| P/E (forward) | 0.8× | — | — | — |
| Free-cash-flow yield | 186.61% | — | — | Top 1% |
| Earnings yield | 132.12% | — | — | Top 1% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -11.1%
- 200-day average slope (20 days)
- -1.2%
- Distance from 50-day average
- -24.7%
- Distance from 200-day average
- -31.7%
- RSI (14)
- 21.9
- Relative volume
- 1.29×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 58.2%
- Volatility vs own 5-year history
- 18th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.66
- Correlation with S&P 500
- 0.14
- Current drawdown from 1-year high
- -53.7%
- Maximum drawdown, 3 years
- -73.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 12, 2021 | Nov 10, 2023 | -98.4% | 652 days | Not yet recovered |
| Oct 8, 2020 | Oct 30, 2020 | -50.6% | 16 days | 82 days (Mar 2, 2021) |
| Mar 2, 2021 | Mar 29, 2021 | -30.5% | 19 days | 8 days (Apr 9, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $67.4M
- P/E (TTM)
- 0.8
- EPS, diluted (TTM)
- $2.68
- Revenue (TTM)
- $68.5M
- 52-week range
- $2.01 – $4.53
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Gross profit | $36.7M | $45.0M | $61.6M | $36.8M | $42.3M |
| Operating income | -$188.5M | -$203.6M | -$142.3M | -$110.4M | -$70.2M |
| Net income | -$64.7M | -$86.6M | -$60.6M | -$46.0M | $6.8M |
| EPS (diluted) | -$11.85 | -$14.55 | -$8.47 | -$2.69 | -$0.05 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.6M | $15.1M | $13.1M | $16.4M | $17.6M | $16.1M | $16.0M | $18.7M |
| Net income | -$12.9M | -$6.8M | -$10.6M | $15.5M | $5.8M | -$3.9M | $110.4M | -$468,000 |
| EPS (diluted) | -$0.76 | -$0.37 | -$0.48 | $0.45 | $0.11 | -$0.17 | $2.82 | -$0.08 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$116.5M | -$179.4M | -$128.2M | -$80.2M | -$65.8M |
| Capital expenditure | -$16.3M | -$3.1M | -$8.1M | -$15.0M | $0 |
| Free cash flow | -$132.9M | -$182.5M | -$136.3M | -$95.2M | -$65.8M |
| Dividends paid | -$749,000 | -$749,000 | -$736,000 | -$694,000 | -$664,000 |
| Net share buybacks | $155.3M | $39.1M | $80.4M | $82.8M | $84.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $196.6M
- Total assets
- $316.7M
- Total liabilities
- $110.6M
- Total debt
- $64.8M
- Net debt
- -$131.8M
- Shareholders’ equity
- $164.1M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 5,107,594
- Days to cover
- 18.97
- Change vs previous report
- -6.2%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Oct 10, 2023
- 1-for-15